T cell Bim levels reflect responses to anti–PD-1 cancer therapy

Immune checkpoint therapy with PD-1 blockade has emerged as an effective therapy for many advanced cancers; however, only a small fraction of patients achieve durable responses. To date, there is no validated blood-based means of predicting the response to PD-1 blockade. We report that Bim is a down...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Dronca, Roxana S., Liu, Xin, Harrington, Susan M., Chen, Lingling, Cao, Siyu, Kottschade, Lisa A., McWilliams, Robert R., Block, Matthew S., Nevala, Wendy K., Thompson, Michael A., Mansfield, Aaron S., Park, Sean S., Markovic, Svetomir N., Dong, Haidong
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4863706/
https://ncbi.nlm.nih.gov/pubmed/27182556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.86014
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados